Moors & Cabot Inc. Has $22.60 Million Holdings in Johnson & Johnson $JNJ

Moors & Cabot Inc. reduced its position in Johnson & Johnson (NYSE:JNJ) by 3.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 121,865 shares of the company’s stock after selling 4,551 shares during the period. Johnson & Johnson comprises approximately 1.0% of Moors & Cabot Inc.’s holdings, making the stock its 13th largest position. Moors & Cabot Inc.’s holdings in Johnson & Johnson were worth $22,596,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Abich Financial Wealth Management LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth approximately $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter worth $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $28,000. Semmax Financial Advisors Inc. grew its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc raised its position in Johnson & Johnson by 707.1% during the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after buying an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Morgan Stanley set a $262.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $235.91.

Johnson & Johnson Price Performance

NYSE JNJ opened at $243.03 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $585.37 billion, a PE ratio of 21.99, a price-to-earnings-growth ratio of 2.38 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The company has a 50 day moving average price of $232.69 and a two-hundred day moving average price of $207.13.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 over the last three months. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.